GLP-1 therapy works through mechanisms that are fundamentally the same in men and women, but the research suggests that sex-based biological differences, from baseline hormone levels to body composition to metabolic rate, may influence both the pattern and magnitude of weight loss. Understanding these differences helps set appropriate expectations and enables better individualization of treatment.

Most large GLP-1 trials enrolled both men and women and reported overall averages. When researchers have examined sex-stratified subgroup analyses, the picture is nuanced.

In the STEP 1 trial of semaglutide, women achieved slightly higher mean percentage weight loss than men, a finding that has been observed in several GLP-1 studies. However, when weight loss is measured in absolute pounds rather than percentage, the difference often narrows or disappears because men generally start at higher absolute weights.

The SURMOUNT-1 trial of tirzepatide showed similar patterns. Both sexes achieved clinically meaningful weight loss, and both showed dose-dependent responses, but the magnitude of percentage weight loss was somewhat higher in female participants.

Men and women have different baseline body compositions. Men typically carry more lean muscle mass and a different distribution of fat compared to women. Because muscle mass is metabolically active, men tend to have higher basal metabolic rates at equivalent weights. This affects how weight loss manifests: men may lose weight faster initially because their higher metabolic baseline amplifies the caloric deficit created by appetite suppression, but the distribution of where that weight comes from may differ.

GLP-1 medications reduce overall energy intake, but they do not specifically target fat over muscle. Research suggests that protein intake during GLP-1 therapy is particularly important for preserving muscle mass, and this may be especially relevant for men who have more lean mass at stake.

Estrogen influences both fat distribution and metabolic regulation. Women with higher estrogen levels tend to store fat peripherally (hips, thighs), while lower estrogen states associated with menopause shift fat storage centrally (abdomen). GLP-1 therapy affects appetite and caloric intake, but the distribution of where fat is lost may be influenced by the underlying hormonal environment.

Testosterone in men influences insulin sensitivity and fat metabolism. Men with lower testosterone, a common condition called hypogonadism that becomes more prevalent with age, may have different metabolic responses to GLP-1 therapy than men with normal testosterone levels.

Women naturally have slower gastric emptying than men on average. Since GLP-1 medications further slow gastric emptying, women may be more sensitive to the nausea and gastrointestinal side effects that result from this mechanism. Clinical experience with GLP-1 therapy consistently shows that women report nausea more frequently than men, a pattern consistent with the baseline gastric physiology difference.

Research on GLP-1 adherence has not shown dramatic sex differences overall, but women are more likely to seek medical care generally and may access follow-up support more readily. Programs with active physician oversight and community support may particularly benefit women, who research suggests are more likely to engage with social accountability structures.

As noted above, nausea and gastrointestinal side effects appear more prevalent in women on GLP-1 therapy, likely related to the pre-existing baseline of slower gastric emptying. This makes careful dose escalation particularly important for female patients. Starting at a low dose and increasing slowly, pausing escalation if nausea is significant, is especially relevant for women.

Men may be more prone to muscle loss during GLP-1 therapy due to higher baseline lean mass and potentially lower protein intake. Prioritizing protein intake and maintaining resistance training during GLP-1 treatment is important for both sexes but particularly for men who want to preserve their muscle mass during weight loss.

The sex differences in GLP-1 response are real but not dramatic enough to fundamentally change whether the therapy is appropriate for either group. Both men and women achieve meaningful, clinically significant weight loss. The differences are nuanced and individual, not categorical.

What sex-based differences do support is the importance of individualized dosing, close monitoring of side effects with particular attention to gastrointestinal tolerance in women, and specific attention to muscle preservation in men. A physician-supervised program that individualizes your treatment based on your response, rather than applying a one-size protocol, is the approach most likely to optimize outcomes regardless of sex.


Individual results may vary. All prescriptions require approval by a licensed medical provider. Compounded medications are not FDA-approved. EllieMD facilitates access to independent healthcare providers and pharmacies and does not provide medical care or dispense medications.